Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

Bristol Myers (BMY) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for the immunotherapy drug, Opdivo (nivolumab), in combination with Yervoy (ipilimumab).The sBLA seeks approval of Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable hepatocellular carcinoma (HCC). A final decision from the regulatory body in the United States is expected on Apr 21, 2025.Bristol Myers’ application is based on results from the late-stag ...